HomeNewsBusinessCoronavirus lockdown | Apparel sector likely to witness 10-15% revenue loss in FY21: ICRA

Coronavirus lockdown | Apparel sector likely to witness 10-15% revenue loss in FY21: ICRA

ICRA in a report said that it expects high operating leverage, discounted sales to clear inventory backlog and bad debts to result in a shrinkage of their profit margins.

April 02, 2020 / 17:56 IST
Story continues below Advertisement

In the wake of the rapid spread of COVID-19 pandemic that has brought demand to a standstill, revenues of Indian apparel players are likely to fall by at least 10-15 per cent in 2020-21, according to a report.

Although companies are likely to undertake some cost rationalisation measures such as employee base optimisation, pay cuts, promotional budget cuts and rental renegotiations, Icra in a report said that it expects high operating leverage, discounted sales to clear inventory backlog and bad debts to result in a shrinkage of their profit margins.

Story continues below Advertisement

This will also impact the revenues of apparel players by 10-15 per cent in FY21 it added.

“With the 21-day domestic lockdown announced by the government from March 25 onwards to combat the spread of the virus, domestic apparel sales have come to a complete halt.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show